Immunocore Holdings (IMCR) said Tuesday that the National Institute for Health and Care Excellence has recommended Kimmtrak for funding through the National Health Service in England.
The National Institute for Health recommended Kimmtrak within its marketing authorization to treat adults with unresectable or metastatic uveal melanoma, the company said, adding that the NICE initially declared a "negative decision" in May last year for Kimmtrak, which Immunocore appealed in December 2023.
Kimmtrak is now funded on the National Health Service in England as of Dec. 2, the company said.
Shares of the company were up 2.7% in recent Tuesday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。